Key clinical point: Belimumab came up short for the treatment of systemic lupus erythematosus in black patients.
Major finding: The B-cell activating factor inhibitor missed all of its primary and secondary endpoints in the Food and Drug Administration–required postmarketing study.
Study details: This was a 52-week, double-blind, placebo-controlled, phase 3/4, multinational, randomized trial including 503 black systemic lupus erythematosus patients.
Disclosures: The EMBRACE trial was sponsored by GlaxoSmithKline. The presenter reported receiving research funding from that pharmaceutical company and several others, the National Institutes of Health, and the Department of Veterans Affairs.
Oates JC et al. Lupus Sci Med. 2019;6[suppl 1], Abstract 200.